"Pyrazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
| Descriptor ID |
D011720
|
| MeSH Number(s) |
D03.383.129.539
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrazoles".
Below are MeSH descriptors whose meaning is more specific than "Pyrazoles".
This graph shows the total number of publications written about "Pyrazoles" by people in this website by year, and whether "Pyrazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 2 | 0 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 3 | 3 | 6 |
| 2001 | 1 | 3 | 4 |
| 2002 | 1 | 9 | 10 |
| 2003 | 0 | 4 | 4 |
| 2004 | 3 | 11 | 14 |
| 2005 | 6 | 3 | 9 |
| 2006 | 6 | 6 | 12 |
| 2007 | 7 | 4 | 11 |
| 2008 | 12 | 5 | 17 |
| 2009 | 11 | 6 | 17 |
| 2010 | 14 | 4 | 18 |
| 2011 | 14 | 5 | 19 |
| 2012 | 21 | 16 | 37 |
| 2013 | 24 | 10 | 34 |
| 2014 | 25 | 11 | 36 |
| 2015 | 38 | 17 | 55 |
| 2016 | 31 | 19 | 50 |
| 2017 | 34 | 18 | 52 |
| 2018 | 50 | 21 | 71 |
| 2019 | 29 | 26 | 55 |
| 2020 | 21 | 21 | 42 |
| 2021 | 24 | 21 | 45 |
| 2022 | 3 | 33 | 36 |
| 2023 | 3 | 12 | 15 |
| 2024 | 17 | 19 | 36 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrazoles" by people in Profiles.
-
ATR inhibition radiosensitizes cells through augmented DNA damage and G2 cell cycle arrest abrogation. JCI Insight. 2024 Oct 08; 9(19).
-
Can Ruxolitinib Crash TET2- and IDH2-Driven Clonal Hematopoiesis? Cancer Discov. 2024 Oct 04; 14(10):1768-1770.
-
Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Blood. 2024 09 26; 144(13):1374-1386.
-
Dual optical elastography detects TGF-? -induced alterations in the biomechanical properties of skin scaffolds. J Biomed Opt. 2024 Sep; 29(9):095002.
-
Clinical implications of combination proton pump inhibitor and triple therapies in patients with atrial fibrillation following percutaneous intervention: a guide for clinicians. Expert Rev Cardiovasc Ther. 2024 Sep; 22(9):483-491.
-
Safety and efficacy of luspatercept for the treatment of anemia in?patients with myelofibrosis. Blood Adv. 2024 09 10; 8(17):4511-4522.
-
Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib. Blood Adv. 2024 09 10; 8(17):4487-4501.
-
Momelotinib for the treatment of myelofibrosis. Blood. 2024 08 15; 144(7):708-713.
-
Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. J Clin Oncol. 2024 Sep 20; 42(27):3187-3195.
-
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature. Expert Opin Pharmacother. 2024 Jul; 25(10):1391-1404.